KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to -$131.6 million.

  • Sarepta Therapeutics' Change in Receivables fell 27652.13% to -$131.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.8 million, marking a year-over-year decrease of 13353.1%. This contributed to the annual value of $201.7 million for FY2024, which is 859.56% up from last year.
  • As of Q3 2025, Sarepta Therapeutics' Change in Receivables stood at -$131.6 million, which was down 27652.13% from -$132.1 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Change in Receivables high stood at $167.5 million for Q4 2024, and its period low was -$132.1 million during Q2 2025.
  • Its 5-year average for Change in Receivables is $15.5 million, with a median of $13.1 million in 2022.
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 359880.6% in 2023, then crashed by 60219.58% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Change in Receivables (Quarter) stood at $3.2 million in 2021, then skyrocketed by 309.58% to $13.1 million in 2022, then soared by 521.02% to $81.5 million in 2023, then soared by 105.55% to $167.5 million in 2024, then tumbled by 178.56% to -$131.6 million in 2025.
  • Its last three reported values are -$131.6 million in Q3 2025, -$132.1 million for Q2 2025, and $57.4 million during Q1 2025.